Vanguard Group Inc lifted its holdings in Corvus Pharmaceuticals Inc (NASDAQ:CRVS) by 2.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 677,974 shares of the company’s stock after acquiring an additional 13,578 shares during the quarter. Vanguard Group Inc owned approximately 2.32% of Corvus Pharmaceuticals worth $5,817,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in the company. Schwab Charles Investment Management Inc. boosted its holdings in shares of Corvus Pharmaceuticals by 48.0% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 25,900 shares of the company’s stock worth $285,000 after acquiring an additional 8,400 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in Corvus Pharmaceuticals by 35.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 37,099 shares of the company’s stock worth $407,000 after buying an additional 9,782 shares in the last quarter. Trexquant Investment LP acquired a new position in Corvus Pharmaceuticals during the 3rd quarter worth $107,000. Acadian Asset Management LLC lifted its holdings in Corvus Pharmaceuticals by 59.2% during the 3rd quarter. Acadian Asset Management LLC now owns 34,229 shares of the company’s stock worth $293,000 after buying an additional 12,735 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Corvus Pharmaceuticals by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 677,974 shares of the company’s stock worth $5,817,000 after buying an additional 13,578 shares in the last quarter. 88.32% of the stock is currently owned by institutional investors and hedge funds.
Several research analysts have issued reports on the company. Cowen reaffirmed a “buy” rating on shares of Corvus Pharmaceuticals in a report on Friday, November 2nd. Zacks Investment Research upgraded shares of Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating and set a $8.75 target price for the company in a research report on Wednesday, November 7th. Finally, ValuEngine cut shares of Corvus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 21st. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $12.08.
NASDAQ:CRVS traded up $0.30 during mid-day trading on Monday, reaching $4.52. The stock had a trading volume of 3,030 shares, compared to its average volume of 101,309. The stock has a market capitalization of $123.57 million, a price-to-earnings ratio of -1.66 and a beta of 0.99. Corvus Pharmaceuticals Inc has a 12 month low of $3.22 and a 12 month high of $13.91.
In other news, CEO Richard A. Md Miller acquired 20,000 shares of Corvus Pharmaceuticals stock in a transaction on Thursday, December 27th. The stock was acquired at an average cost of $3.29 per share, for a total transaction of $65,800.00. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Richard A. Md Miller acquired 5,000 shares of Corvus Pharmaceuticals stock in a transaction on Thursday, December 6th. The shares were purchased at an average price of $5.99 per share, with a total value of $29,950.00. The disclosure for this purchase can be found here. Over the last three months, insiders have bought 81,202 shares of company stock valued at $316,992. 39.50% of the stock is currently owned by insiders.
Corvus Pharmaceuticals Company Profile
Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies that are designed to harness the immune system to attack cancer cells. Its lead product candidate is CPI-444, an oral, small molecule antagonist of the A2A receptor that is in Phase I/Ib clinical trial for adenosine, an immune checkpoint.
Recommended Story: What factors cause inflation to rise?
Want to see what other hedge funds are holding CRVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corvus Pharmaceuticals Inc (NASDAQ:CRVS).